Designing universal T cell therapies: strategies to evade natural killer cells - Takeaways - MDSpire

Designing universal T cell therapies: strategies to evade natural killer cells

  • By

  • Omar Bushara

  • Gerald P. Linette

  • Beatriz M. Carreno

  • May 20, 2026

  • 0 min

Share

  • 1

    Adoptive T cell therapy (ACT) utilizes autologous T cells for cancer treatment, but poses scientific and logistical challenges.

  • 2

    Universal allogeneic T cell products from healthy donors may overcome limitations of autologous therapies, offering scalable solutions.

  • 3

    Strategies to evade host immune responses include HLA ablation and enhancing HLA-E expression to reduce NK cell-mediated rejection.

  • 4

    Genetic ablation of TCR and CD3 components in donor T cells mitigates alloreactivity and the risk of Graft versus Host Disease.

  • 5

    Current advancements suggest that off-the-shelf universal T cell products could become standard treatment options for certain cancers.

Original Source(s)

Designing universal T cell therapies: strategies to evade natural killer cells

  • by Omar Bushara, Gerald P. Linette, Beatriz M. Carreno

  • May 20, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report